Dihexa
Angiotensin IV derived hepatocyte growth factor potentiator
A small molecule studied for synaptogenesis through the HGF and c-Met signaling pathway.
How it works
Potentiates hepatocyte growth factor binding at the c-Met receptor, which drives dendritic spine formation and new synapse assembly in hippocampal models.
What research has shown
Rodent studies report reversal of cognitive deficits in scopolamine and lesion models at very low doses, with reported potency far above BDNF in vitro. No human trials exist.
Reported ranges in the literature
Low end
Animal model doses only
Optimal
No established human range
High end
Not characterized in humans
Frequency reported in the literature: Not established. Note: Preclinical only. Its synaptogenic potency is also the basis of caution in the literature.
Protocol duration and pairing
Typical study duration
2 to 8 weeks in the reported animal cognition models.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.